Can nanomedicines kill cancer stem cells?

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1763-1783

  Zhao, Yi ^a   Alakhova, Daria Y ^a   Kabanov, Alexander V ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cancer; Cancer stem cells; Drug delivery; Nanomedicine; Polymer therapeutics

Indexed keywords

BIOLOGICAL PROCESS; CANCER; CANCER STEM CELLS; CHEMOTHERAPEUTIC DRUGS; MAGNETIC NANO-PARTICLES; PLURONIC BLOCK COPOLYMERS; POLYMER THERAPEUTICS; THERAPEUTIC AGENTS;

AGENTS; BIOCHEMISTRY; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; FUNCTIONAL POLYMERS; GENE THERAPY; STEM CELLS; TUMORS;

MEDICAL NANOTECHNOLOGY;

BEVACIZUMAB; BMS 833923; BREAST CANCER RESISTANCE PROTEIN; CARBON NANOTUBE; CISPLATIN; COPOLYMER; CURCUMIN; CYCLOPHOSPHAMIDE; DEMCIZUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LETROZOLE; MAGNETIC NANOPARTICLE; METFORMIN; MK 0752; NANOCARRIER; NATURAL PRODUCT; NUCLEIC ACID; OMP 18R 5; OMP 21 M 18; PACLITAXEL; POLOXAMER; SALINOMYCIN; SMALL INTERFERING RNA; SULFORAPHANE; SUNITINIB; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANTICTUMAB; VISMODEGIB;

BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL CLONE; CELL DEATH; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL ISOLATION; CELL METABOLISM; CELL RENEWAL; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; EMBRYONIC STEM CELL; HUMAN; LUNG NON SMALL CELL CANCER; METABOLIC DISORDER; METASTASIS; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL NICHE; TARGET CELL DESTRUCTION;

CANCER; CANCER STEM CELLS; DRUG DELIVERY; NANOMEDICINE; POLYMER THERAPEUTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; NEOPLASTIC STEM CELLS; PARTICLE SIZE;

EID: 84888205371     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.016     Document Type: Review

References (271)

1. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
2. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
3. Clarke M.F., Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124:1111-1115.
4. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
5. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
6. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
7. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
8. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
9. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
10. Liu Y.P., Yang C.J., Huang M.S., Yeh C.T., Wu A.T., Lee Y.C., Lai T.C., Lee C.H., Hsiao Y.W., Lu J., Shen C.N., Lu P.J., Hsiao M. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013, 73:406-416.
11. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2784-2789.
12. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
13. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
14. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13820-13825.
15. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145:182-195.
16. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 2004, 56:491-509.
17. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54:759-779.
18. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
19. Bae Y., Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev. 2009, 61:768-784.
20. Kakizawa Y., Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. 2002, 54:203-222.
21. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
22. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61:721-731.
23. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 2007, 24:438-449.
24. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
25. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 2005, 57:609-636.
26. Constantinides P.P., Chaubal M.V., Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 2008, 60:757-767.
27. Rana S., Bajaj A., Mout R., Rotello V.M. Monolayer coated gold nanoparticles for delivery applications. Adv. Drug Deliv. Rev. 2012, 64:200-216.
28. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 2008, 60:1307-1315.
29. Sun C., Lee J.S., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1252-1265.
30. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
31. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
32. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
33. Zamboni W.C., Torchilin V., Patri A.K., Hrkach J., Stern S., Lee R., Nel A., Panaro N.J., Grodzinski P. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin. Cancer Res. 2012, 18:3229-3241.
34. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
35. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001, 19:3312-3322.
36. Gordon A.N., Tonda M., Sun S., Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 2004, 95:1-8.
37. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 1998, 77:396-401.
38. Luo Y., Bernshaw N.J., Lu Z.R., Kopecek J., Prestwich G.D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 2002, 19:396-402.
39. Lee K., Drachev V.P., Irudayaraj J. DNA-gold nanoparticle reversible networks grown on cell surface marker sites: application in diagnostics. ACS Nano 2011, 5:2109-2117.
40. Swaminathan S.K., Roger E., Toti U., Niu L., Ohlfest J.R., Panyam J. CD133-Targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Control. Release 2013, 171:280-287.
41. Wei X., Senanayake T.H., Warren G., Vinogradov S.V. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug. Chem. 2013, 24:658-668.
42. Xu Y., Chenna V., Hu C., Sun H.X., Khan M., Bai H., Yang X.R., Zhu Q.F., Sun Y.F., Maitra A., Fan J., Anders R.A. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2012, 18:1291-1302.
43. Liu Y., Lu W.L., Guo J., Du J., Li T., Wu J.W., Wang G.L., Wang J.C., Zhang X., Zhang Q. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 2008, 129:18-25.
44. Zhou Y., Yang J., Kopecek J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 2012, 33:1863-1872.
45. Sadhukha T., Niu L., Wiedmann T.S., Panyam J. Effective elimination of cancer stem cells by magnetic hyperthermia. Mol. Pharm. 2013, 10:1432-1441.
46. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M., Invernici G., Parati E., Alessandri G., La Porta C.A. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43:935-946.
47. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26:3008-3017.
48. Welte Y., Adjaye J., Lehrach H.R., Regenbrecht C.R. Cancer stem cells in solid tumors: elusive or illusive?. Cell Commun. Signal. 2010, 8:6.
49. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
50. Gibbs K.D., Jager A., Crespo O., Goltsev Y., Trejo A., Richard C.E., Nolan G.P. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 2012, 10:210-217.
51. Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., Woll P., Mead A., Alford K.A., Rout R., Chaudhury S., Gilkes A., Knapper S., Beldjord K., Begum S., Rose S., Geddes N., Griffiths M., Standen G., Sternberg A., Cavenagh J., Hunter H., Bowen D., Killick S., Robinson L., Price A., Macintyre E., Virgo P., Burnett A., Craddock C., Enver T., Jacobsen S.E., Porcher C., Vyas P. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
52. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., Abel U., Arens A., Weichert W., Brand K., Koch M., Weitz J., Schmidt M., von Kalle C., Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
53. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805:105-117.
54. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000, 21:497-503.
55. Lu C.L., Guo J., Gu J., Ge D., Hou Y.Y., Lin Z.W., Ding J.Y. CXCR4 heterogeneous expression in esophageal squamous cell cancer and stronger metastatic potential with CXCR4-positive cancer cells. Dis. Esophagus 2013, (in press). 10.1111/dote.12100.
56. Fidler I.J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. 2001, 93:1040-1041.
57. Rottenberg S., Vollebergh M.A., de Hoon B., de Ronde J., Schouten P.C., Kersbergen A., Zander S.A., Pajic M., Jaspers J.E., Jonkers M., Loden M., Sol W., van der Burg E., Wesseling J., Gillet J.P., Gottesman M.M., Gribnau J., Wessels L., Linn S.C., Jonkers J., Borst P. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res. 2012, 72:2350-2361.
58. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
59. Longo D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 2012, 366:956-957.
60. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
61. Powell A.A., Talasaz A.H., Zhang H., Coram M.A., Reddy A., Deng G., Telli M.L., Advani R.H., Carlson R.W., Mollick J.A., Sheth S., Kurian A.W., Ford J.M., Stockdale F.E., Quake S.R., Pease R.F., Mindrinos M.N., Bhanot G., Dairkee S.H., Davis R.W., Jeffrey S.S. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PloS ONE 2012, 7:e33788.
62. Rottenberg S., Nygren A.O., Pajic M., van Leeuwen F.W., van der Heijden I., van de Wetering K., Liu X., de Visser K.E., Gilhuijs K.G., van Tellingen O., Schouten J.P., Jonkers J., Borst P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12117-12122.
63. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond.) 2012, 7:597-615.
64. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
65. Xu W., Debeb B.G., Lacerda L., Li J., Woodward W.A. Tetrandrine, a compound common in Chinese traditional medicine, preferentially kills breast cancer tumor initiating cells (TICs) in vitro. Cancers 2011, 3:2274-2285.
66. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sanchez V., Sanders M., Stanford J., Cook R.S., Arteaga C.L. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Investig. 2013, 123:1348-1358.
67. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15:338-344.
68. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012, 2012:11.
69. He S., Nakada D., Morrison S.J. Mechanisms of stem cell self-renewal. Annu. Rev. Cell Dev. Biol. 2009, 25:377-406.
70. Li L., Bhatia R. Stem cell quiescence. Clin. Cancer Res. 2011, 17:4936-4941.
71. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14:3-9.
72. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
73. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
74. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.
75. Williams R.T., den Besten W., Sherr C.J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007, 21:2283-2287.
76. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
77. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7950-7955.
78. Vermeulen L., de Sousa e Melo F., Richel D.J., Medema J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13:e83-e89.
79. Rowan K. Are cancer stem cells real? After four decades, debate still simmers. J. Natl. Cancer Inst. 2009, 101:546-547.
80. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., Morrison S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
81. Kamohara Y., Haraguchi N., Mimori K., Tanaka F., Inoue H., Mori M., Kanematsu T. The search for cancer stem cells in hepatocellular carcinoma. Surgery 2008, 144:119-124.
82. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Molecular cancer research: MCR 2009, 7:989-999.
83. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512.
84. Britton K.M., Eyre R., Harvey I.J., Stemke-Hale K., Browell D., Lennard T.W., Meeson A.P. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012, 323:97-105.
85. Kim J.B., Ko E., Han W., Shin I., Park S.Y., Noh D.Y. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med. 2008, 74:1693-1700.
86. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183:1797-1806.
87. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67:4827-4833.
88. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14228-14233.
89. Van den Broeck A., Gremeaux L., Topal B., Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 2012, 12:354.
90. Yin L., Castagnino P., Assoian R.K. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res. 2008, 68:800-807.
91. Rabindran S.K., He H., Singh M., Brown E., Collins K.I., Annable T., Greenberger L.M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 1998, 58:5850-5858.
92. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60:47-50.
93. Woehlecke H., Osada H., Herrmann A., Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer 2003, 107:721-728.
94. Zhao S., Smith K.S., Deveau A.M., Dieckhaus C.M., Johnson M.A., Macdonald T.L., Cook J.M. Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. J. Med. Chem. 2002, 45:1559-1562.
95. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004, 64:1242-1246.
96. Raaijmakers M.H., de Grouw E.P., Heuver L.H., van der Reijden B.A., Jansen J.H., Scheper R.J., Scheffer G.L., de Witte T.J., Raymakers R.A. Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin. Cancer Res. 2005, 11:2436-2444.
97. Jang J.Y., Kim M.K., Jeon Y.K., Joung Y.K., Park K.D., Kim C.W. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp. Mol. Med. 2012, 44:251-259.
98. Angelastro J.M., Lame M.W. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol. Cancer Res. 2010, 8:1105-1115.
99. Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., Sayegh M.H., Frank M.H. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 2003, 278:47156-47165.
100. Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., Gasser M., Sayegh M.H., Sadee W., Frank M.H. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005, 65:4320-4333.
101. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., Fuhlbrigge R.C., Kupper T.S., Sayegh M.H., Frank M.H. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
102. Zabierowski S.E., Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell 2008, 13:185-187.
103. Kroger N., Achterrath W., Hegewisch-Becker S., Mross K., Zander A.R. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat. Rev. 1999, 25:279-291.
104. Dalton W.S., Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin. Oncol. 1999, 26:23-27.
105. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
106. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002, 5:349-355.
107. Naito S., Yokomizo A., Koga H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int. J. Urol. 1999, 6:427-439.
108. Thomas M., Klibanov A.M. Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 2003, 62:27-34.
109. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., BeketicOreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 1997, 40:S13-S19.
110. Kostakoglu L., Elahi N., Uzal D., Khademi B., Atahan L., Bekdik C.F. Double-phase Tc-99m-SestaMIBI SPECT imaging in a case of glomus jugulare tumor. Radiat. Med. 1997, 15:331-334.
111. Qiang L., Yang Y., Ma Y.J., Chen F.H., Zhang L.B., Liu W., Qi Q., Lu N., Tao L., Wang X.T., You Q.D., Guo Q.L. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 2009, 279:13-21.
112. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., Pratesi G., Fabbri A., Andriani F., Tinelli S., Roz E., Caserini R., Lo Vullo S., Camerini T., Mariani L., Delia D., Calabro E., Pastorino U., Sozzi G. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16281-16286.
113. Yang C., Xiong F., Wang J., Dou J., Chen J., Chen D., Zhang Y., Luo S., Gu N. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond.) 2013, (in press). 10.2217/nnm.12.216.
114. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., Ng I., Man K., Wong N., To K.F., Zheng B.J., Lai P.B., Lo C.M., Chan K.W., Guan X.Y. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
115. Emmink B.L., Van Houdt W.J., Vries R.G., Hoogwater F.J., Govaert K.M., Verheem A., Nijkamp M.W., Steller E.J., Jimenez C.R., Clevers H., Borel Rinkes I.H., Kranenburg O. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011, 141:269-278.
116. Gazzaniga P., Cigna E., Panasiti V., Devirgiliis V., Bottoni U., Vincenzi B., Nicolazzo C., Petracca A., Gradilone A. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. Eur. J. Surg. Oncol. 2010, 36:1211-1214.
117. Grimm M., Krimmel M., Polligkeit J., Alexander D., Munz A., Kluba S., Keutel C., Hoffmann J., Reinert S., Hoefert S. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur. J. Cancer 2012, 48:3186-3197.
118. Czyz M., Koprowska K., Sztiller-Sikorska M. Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol. Ther. 2013, 14:135-145.
119. Cheung S.T., Cheung P.F., Cheng C.K., Wong N.C., Fan S.T. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011, 140:344-355.
120. Lonergan T., Brenner C., Bavister B. Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. J. Cell. Physiol. 2006, 208:149-153.
121. Parker G.C., Acsadi G., Brenner C.A. Mitochondria: determinants of stem cell fate?. Stem Cells Dev. 2009, 18:803-806.
122. Ye X.Q., Wang G.H., Huang G.J., Bian X.W., Qian G.S., Yu S.C. Heterogeneity of mitochondrial membrane potential: a novel tool to isolate and identify cancer stem cells from a tumor mass?. Stem Cell Rev. 2011, 7:153-160.
123. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O'Dwyer K.M., Liesveld J.L., Brookes P.S., Becker M.W., Jordan C.T. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12:329-341.
124. Vlashi E., Lagadec C., Vergnes L., Matsutani T., Masui K., Poulou M., Popescu R., Della Donna L., Evers P., Dekmezian C., Reue K., Christofk H., Mischel P.S., Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16062-16067.
125. Schieke S.M., Ma M., Cao L., McCoy J.P., Liu C., Hensel N.F., Barrett A.J., Boehm M., Finkel T. Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J. Biol. Chem. 2008, 283:28506-28512.
126. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
127. Campbell C., Risueno R.M., Salati S., Guezguez B., Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr. Opin. Hematol. 2008, 15:319-325.
128. Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 2007, 13:4042-4045.
129. Rattis F.M., Voermans C., Reya T. Wnt signaling in the stem cell niche. Curr. Opin. Hematol. 2004, 11:88-94.
130. DiMeo T.A., Anderson K., Phadke P., Fan C., Perou C.M., Naber S., Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69:5364-5373.
131. Khramtsov A.I., Khramtsova G.F., Tretiakova M., Huo D., Olopade O.I., Goss K.H. Wnt/[beta]-Catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 2010, 176:2911-2920.
132. Rieger M.E., Sims A.H., Coats E.R., Clarke R.B., Briegel K.J. The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol. Cell. Biol. 2010, 30:4267-4279.
133. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
134. Gurney A., Axelrod F., Bond C.J., Cain J., Chartier C., Donigan L., Fischer M., Chaudhari A., Ji M., Kapoun A.M., Lam A., Lazetic S., Ma S., Mitra S., Park I.K., Pickell K., Sato A., Satyal S., Stroud M., Tran H., Yen W.C., Lewicki J., Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11717-11722.
135. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005, 65:6207-6219.
136. Schott A.F., Landis M.D., Dontu G., Griffith K.A., Layman R.M., Krop I., Paskett L.A., Wong H., Dobrolecki L.E., Lewis M.T., Froehlich A.M., Paranilam J., Hayes D.F., Wicha M.S., Chang J.C. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin. Cancer Res. 2013, 19:1512-1524.
137. Shih Ie M., Wang T.L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007, 67:1879-1882.
138. Yen W.C., Fischer M.M., Hynes M., Wu J.J., Kim E., Beviglia L., Yeung V.P., Song X.M., Kapoun A.M., Lewicki J., Gurney A., Simeone D.M., Hoey T. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin. Cancer Res. 2012, 18:5374-5386.
139. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., Singh M., Chien M., Tan C., Hongo J.A.S., de Sauvage F., Plowman G., Yan M.H. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
140. Bhat-Nakshatri P., Goswami C.P., Badve S., Sledge G.W., Nakshatri H. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci. Rep. 2013, 3:2530.
141. Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010, 1:387-395.
142. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
143. Dou J., Gu N. Emerging strategies for the identification and targeting of cancer stem cells. Tumour Biol. 2010, 31:243-253.
144. Schatton T., Frank N.Y., Frank M.H. Identification and targeting of cancer stem cells. BioEssays 2009, 31:1038-1049.
145. Cho R.W., Wang X., Diehn M., Shedden K., Chen G.Y., Sherlock G., Gurney A., Lewicki J., Clarke M.F. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008, 26:364-371.
146. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Meth. 2009, 347:70-78.
147. Orford K.W., Scadden D.T. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat. Rev. Genet. 2008, 9:115-128.
148. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11154-11159.
149. Chiba T., Kita K., Zheng Y.W., Yokosuka O., Saisho H., Iwama A., Nakauchi H., Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
150. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
151. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 2007, 1:485-487.
152. Singh B.N., Fu J.S., Srivastava R.K., Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PloS ONE 2011, 6.
153. Steven D.H., Gendreau B., Ho Ching-Ping, Lewin Anne, Lin Tara, Merchant Akil, Rowley R.Bruce, Wang Qiuju, Matsui William, Fargnoli Joseph Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development [abstract]. Mol. Cancer Ther. 2009, 8(Supplement 1). 10.1158/1535-7163.TARG-1109-B1192.
154. Low J.A., de Sauvage F.J. Clinical experience with hedgehog pathway inhibitors. J. Clin. Oncol. 2010, 28:5321-5326.
155. Guan J.L. Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life 2010, 62:268-276.
156. Jiang J., Zhang Y., Chuai S., Wang Z., Zheng D., Xu F., Li C., Liang Y., Chen Z. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 2012, 31:671-682.
157. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., Sozzi G., Fontanella E., Menard S., Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15:2010-2021.
158. Reim F., Dombrowski Y., Ritter C., Buttmann M., Hausler S., Ossadnik M., Krockenberger M., Beier D., Beier C.P., Dietl J., Becker J.C., Honig A., Wischhusen J. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009, 69:8058-8066.
159. Kallifatidis G., Rausch V., Baumann B., Apel A., Beckermann B.M., Groth A., Mattern J., Li Z., Kolb A., Moldenhauer G., Altevogt P., Wirth T., Werner J., Schemmer P., Buchler M.W., Salnikov A.V., Herr I. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009, 58:949-963.
160. Lin L.C., Yeh C.T., Kuo C.C., Lee C.M., Yen G.C., Wang L.S., Wu C.H., Yang W.C., Wu A.T. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/beta-catenin function. J. Agric. Food Chem. 2012, 60:7031-7039.
161. Lin L., Liu Y., Li H., Li P.K., Fuchs J., Shibata H., Iwabuchi Y., Lin J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer 2011, 105:212-220.
162. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., Liu S., Dontu G., Wicha M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 2010, 122:777-785.
163. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
164. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68:3645-3654.
165. Sachlos E., Risueno R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., Malig M., McNicol J.D., Fiebig-Comyn A., Graham M., Levadoux-Martin M., Lee J.B., Giacomelli A.O., Hassell J.A., Fischer-Russell D., Trus M.R., Foley R., Leber B., Xenocostas A., Brown E.D., Collins T.J., Bhatia M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
166. Boehmerle W., Endres M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis. 2011, 2:e168.
167. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann. Intern. Med. 2002, 137:25-33.
168. Kallifatidis G., Labsch S., Rausch V., Mattern J., Gladkich J., Moldenhauer G., Buchler M.W., Salnikov A.V., Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. 2011, 19:188-195.
169. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., Yu Y., Clouthier S.G., Schwartz S.J., Wicha M.S., Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 2010, 16:2580-2590.
170. Duenas-Garcia I.E., Santos-Cruz L.F., Castaneda-Partida L., Castaneda-Sortibran A.N., Ordaz-Tellez M.G., Sanchez-Santos A., Duran-Diaz A., Rodriguez-Arnaiz R., Heres-Pulido M.E. Interactions of sulforaphane and dimethyl sulfoxide with methyl methanesulfonate, urethane, 4-nitroquinoline-1-oxide and hydrogen peroxide in the Drosophila melanogaster wing spot test. Food Chem. Toxicol. 2012, 50:4479-4486.
171. Subramaniam D., Ponnurangam S., Ramamoorthy P., Standing D., Battafarano R.J., Anant S., Sharma P. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PloS ONE 2012, 7:e30590.
172. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4:807-818.
173. Gou S., Cui P., Li X., Shi P., Liu T., Wang C. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PloS ONE 2013, 8:e63969.
174. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., Banerjee S., Kong D., Li Y., Thakur S., Sarkar F.H. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila.) 2012, 5:355-364.
175. Cheng C.L., Yu L.X., Lee H.L., Yang C.Y., Lue C.S., Chou C.H. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur. J. Pharm. Sci. 2004, 22:297-304.
176. Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med. Chem. 2011, 7:106-111.
177. Lu D., Choi M.Y., Yu J., Castro J.E., Kipps T.J., Carson D.A. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13253-13257.
178. Jayashree R. Effect of soil pH on sorption of salinomycin in clay and sandy soils. Afr. J. Environ. Sci. Technol. 2011, 5:661.
179. Shahrokhian S., Ghalkhani M., Adeli M., Amini M.K. Multi-walled carbon nanotubes with immobilised cobalt nanoparticle for modification of glassy carbon electrode: application to sensitive voltammetric determination of thioridazine. Biosens. Bioelectron. 2009, 24:3235-3241.
180. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
181. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
182. Arai F., Hirao A., Suda T. Regulation of hematopoietic stem cells by the niche. Trends Cardiovasc. Med. 2005, 15:75-79.
183. Li L., Neaves W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006, 66:4553-4557.
184. Filatova A., Acker T., Garvalov B.K. The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. BBA 2013, 1830:2496-2508.
185. Borovski T., Melo F.D.E., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res. 2011, 71:634-639.
186. LaBarge M.A. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res. 2010, 16:3121-3129.
187. Zhang M., Behbod F., Atkinson R.L., Landis M.D., Kittrell F., Edwards D., Medina D., Tsimelzon A., Hilsenbeck S., Green J.E., Michalowska A.M., Rosen J.M. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008, 68:4674-4682.
188. Chen S.F., Chang Y.C., Nieh S., Liu C.L., Yang C.Y., Lin Y.S. Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PloS ONE 2012, 7:e31864.
189. Grimshaw M.J., Cooper L., Papazisis K., Coleman J.A., Bohnenkamp H.R., Chiapero-Stanke L., Taylor-Papadimitriou J., Burchell J.M. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10:R52.
190. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., Fields J.Z., Wicha M.S., Boman B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69:3382-3389.
191. Green A.E., Rose P.G. Pegylated liposomal doxorubicin in ovarian cancer. Int. J. Nanomed. 2006, 1:229-239.
192. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 2008, 5:474-486.
193. Chenna V., Hu C., Pramanik D., Aftab B.T., Karikari C., Campbell N.R., Hong S.M., Zhao M., Rudek M.A., Khan S.R., Rudin C.M., Maitra A. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol. Cancer Ther. 2012, 11:165-173.
194. Zhao M.D., Hu F.Q., Du Y.Z., Yuan H., Chen F.Y., Lou M., Yu H.Y. Coadministration of glycolipid-like micelles loading cytotoxic drug with different action site for efficient cancer chemotherapy. Nanotechnology 2009, 20.
195. Song X., Zhao Y., Wu W., Bi Y., Cai Z., Chen Q., Li Y., Hou S. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int. J. Pharm. 2008, 350:320-329.
196. Wong M.Y., Chiu G.N. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs 2010, 21:401-410.
197. Shin H.C., Alani A.W., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 2009, 140:294-300.
198. Han Y., He Z., Schulz A., Bronich T.K., Jordan R., Luxenhofer R., Kabanov A.V. Synergistic combinations of multiple chemotherapeutic agents in high capacity Poly(2-oxazoline) micelles. Mol. Pharm. 2012, 9:2302-2313.
199. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 2002, 1:503-514.
200. Liu C., Tang D.G. MicroRNA regulation of cancer stem cells. Cancer Res. 2011, 71:5950-5954.
201. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS ONE 2009, 4:e6816.
202. Ji Q., Hao X., Meng Y., Zhang M., Desano J., Fan D., Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.
203. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
204. Li Y., Guessous F., Zhang Y., Dipierro C., Kefas B., Johnson E., Marcinkiewicz L., Jiang J., Yang Y., Schmittgen T.D., Lopes B., Schiff D., Purow B., Abounader R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69:7569-7576.
205. Wu Y., Crawford M., Yu B., Mao Y., Nana-Sinkam S.P., Lee L.J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8:1381-1389.
206. Shi S., Han L., Gong T., Zhang Z., Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. Engl. 2013, 52:3901-3905.
207. Liu C., Zhao G., Liu J., Ma N., Chivukula P., Perelman L., Okada K., Chen Z., Gough D., Yu L. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 2009, 140:277-283.
208. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
209. Scott A.M., Allison J.P., Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012, 12:14.
210. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
211. Gao X., Luo Y., Wang Y., Pang J., Liao C., Lu H., Fang Y. Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. Int. J. Nanomed. 2012, 7:4037-4051.
212. Hermansen S.K., Christensen K.G., Jensen S.S., Kristensen B.W. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J. Histochem. Cytochem. 2011, 59:391-407.
213. Shigdar S., Qiao L., Zhou S.F., Xiang D., Wang T., Li Y., Lim L.Y., Kong L., Li L., Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330:84-95.
214. Tamura K., Aoyagi M., Wakimoto H., Ando N., Nariai T., Yamamoto M., Ohno K. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J. Neurosurg. 2010, 113:310-318.
215. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
216. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
217. Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., Masuko T., Shimizu T., Ishikawa T., Kai K., Takahashi E., Imamura Y., Baba Y., Ohmura M., Suematsu M., Baba H., Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19:387-400.
218. Gilbertson R.J., Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7:733-736.
219. Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J. Cell. Physiol. 2012, 227:421-430.
220. Song C.W., Park H., Griffin R.J. Improvement of tumor oxygenation by mild hyperthermia. Radiat. Res. 2001, 155:515-528.
221. Jones E.L., Prosnitz L.R., Dewhirst M.W., Marcom P.K., Hardenbergh P.H., Marks L.B., Brizel D.M., Vujaskovic Z. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin. Cancer Res. 2004, 10:4287-4293.
222. Vujaskovic Z., Rosen E.L., Blackwell K.L., Jones E.L., Brizel D.M., Prosnitz L.R., Samulski T.V., Dewhirst M.W. Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. Int. J. Hyperthermia 2003, 19:498-506.
223. Moon E.J., Sonveaux P., Porporato P.E., Danhier P., Gallez B., Batinic-Haberle I., Nien Y.C., Schroeder T., Dewhirst M.W. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20477-20482.
224. Vujaskovic Z., Song C.W. Physiological mechanisms underlying heat-induced radiosensitization. Int. J. Hyperthermia 2004, 20:163-174.
225. Grise K., Kim F., McFadden D. Hyperthermia induces heat-shock protein expression, reduces pancreatic injury, and improves survival in necrotizing pancreatitis. Pancreas 2000, 21:120-125.
226. Eisenberg D.P., Carpenter S.G., Adusumilli P.S., Chan M.K., Hendershott K.J., Yu Z.K., Fong Y.M. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 2010, 148:325-334.
227. Kelleher D.K., Vaupel P. No sustained improvement in tumor oxygenation after localized mild hyperthermia. Adv. Exp. Med. Biol. 2010, 662:393-398.
228. Andrew R.N.S., Burke R., Carroll David L., Torti Frank M., Torti Suzy V. Targeting cancer stem cells with nanoparticle-enabled therapies. J. Mol. Biomark. Diagn. 2012, S8:003. 10.4172/2155-9929.S8-003.
229. Zhang L., Yao H.J., Yu Y., Zhang Y., Li R.J., Ju R.J., Wang X.X., Sun M.G., Shi J.F., Lu W.L. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012, 33:565-582.
230. Creixell M., Bohorquez A.C., Torres-Lugo M., Rinaldi C. EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano 2011, 5:7124-7129.
231. Domenech M., Marrero-Berrios I., Torres-Lugo M., Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano 2013, 7:5091-5101.
232. Mannix R.J., Kumar S., Cassiola F., Montoya-Zavala M., Feinstein E., Prentiss M., Ingber D.E. Nanomagnetic actuation of receptor-mediated signal transduction. Nat. Nanotechnol. 2008, 3:36-40.
233. Klyachko N.L., Sokolsky-Papkov M., Pothayee N., Efremova M.V., Gulin D.A., Pothayee N., Kuznetsov A.A., Majouga A.G., Riffle J.S., Golovin Y.I., Kabanov A.V. Changing the enzyme reaction rate in magnetic nanosuspensions by a non-heating magnetic field. Angew. Chem. Int. Ed. 2012, 51:12016-12019.
234. Burke A.R., Singh R.N., Carroll D.L., Wood J.C., D'Agostino R.B., Ajayan P.M., Torti F.M., Torti S.V. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012, 33:2961-2970.
235. Kabanov A.V., Chekhonin V.P., Alakhov V., Batrakova E.V., Lebedev A.S., Melik-Nubarov N.S., Arzhakov S.A., Levashov A.V., Morozov G.V., Severin E.S., et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett. 1989, 258:343-345.
236. Danson S., Ferry D., Alakhov V., Margison J., Kerr D., Jowle D., Brampton M., Halbert G., Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 2004, 90:2085-2091.
237. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996, 56:3626-3629.
238. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., Gong N., Mosley R.L., Alakhov V.Y., Gendelman H.E., Kabanov A.V. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J. Control. Release 2010, 143:290-301.
239. Alakhova D.Y., Rapoport N.Y., Batrakova E.V., Timoshin A.A., Li S., Nicholls D., Alakhov V.Y., Kabanov A.V. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J. Control. Release 2010, 142:89-100.
240. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 2004, 21:2226-2233.
241. Minko T., Batrakova E.V., Li S., Li Y., Pakunlu R.I., Alakhov V.Y., Kabanov A.V. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control. Release 2005, 105:269-278.
242. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., Campbell S., Corrie P., Rowinsky E.K., Ranson M. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investig. New Drugs 2011, 29:1029-1037.
243. Batrakova E., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 1999, 16:1373-1379.
244. Kabanov A.V., Batrakova E.V., Alakhov V.Y. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J. Control. Release 2003, 91:75-83.
245. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer 2001, 85:1987-1997.
246. Zhang W., Shi Y., Chen Y., Ye J., Sha X., Fang X. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011, 32:2894-2906.
247. Zhang W., Shi Y., Chen Y., Yu S., Hao J., Luo J., Sha X., Fang X. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 2010, 75:341-353.
248. Mu C.F., Balakrishnan P., Cui F.D., Yin Y.M., Lee Y.B., Choi H.G., Yong C.S., Chung S.J., Shim C.K., Kim D.D. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010, 31:2371-2379.
249. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 1999, 16:1366-1372.
250. Hosseinzadeh H., Atyabi F., Dinarvand R., Ostad S.N. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int. J. Nanomedicine 2012, 7:1851-1863.
251. Guan Y., Huang J., Zuo L., Xu J., Si L., Qiu J., Li G. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. Arch. Pharm. Res. 2011, 34:1719-1728.
252. Alakhova D.Y., Zhao Y., Li S., Kabanov A.V. Effect of Doxorubicin/Pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PloS ONE 2013, 8:e72238.
253. Sharma A.K., Zhang L., Li S., Kelly D.L., Alakhov V.Y., Batrakova E.V., Kabanov A.V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release 2008, 131:220-227.
254. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., Alakhova D.Y., Sherman S., Alakhov V.Y., Kabanov A.V. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol. Pharm. 2006, 3:113-123.
255. Weinberg B.D., Krupka T.M., Haaga J.R., Exner A.A. Combination of sensitizing pretreatment and radiofrequency tumor ablation: evaluation in rat model. Radiology 2008, 246:796-803.
256. Krupka T.M., Exner A.A. Structural parameters governing activity of Pluronic triblock copolymers in hyperthermia cancer therapy. Int. J. Hyperthermia 2011, 27:663-671.
257. Dynlacht J.R., Fox M.H. The effect of 45 degrees C hyperthermia on the membrane fluidity of cells of several lines. Radiat. Res. 1992, 130:55-60.
258. Perera R.H., Krupka T.M., Wu H., Traughber B., Dremann D., Broome A.M., Exner A.A. Role of Pluronic block copolymers in modulation of heat shock protein 70 expression. Int. J. Hyperthermia 2011, 27:672-681.
259. Li G.C., Mak J.Y. Re-induction of hsp70 synthesis: an assay for thermotolerance. 1988. Int. J. Hyperthermia 2009, 25:249-257.
260. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1:323-334.
261. Maeda H., Kabanov A. Polymer Drugs in the Clinical Stage: Advantages and Prospects 2003, Springer.
262. Nukolova N.V., Oberoi H.S., Zhao Y., Chekhonin V.P., Kabanov A.V., Bronich T.K. LHRH-Targeted nanogels as a delivery system for cisplatin to ovarian cancer. Mol. Pharm. 2013, (in press). 10.1021/mp4003688.
263. Nukolova N.V., Oberoi H.S., Cohen S.M., Kabanov A.V., Bronich T.K. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials 2011, 32:5417-5426.
264. Batrakova E.V., Gendelman H.E., Kabanov A.V. Cell-mediated drug delivery. Expert Opin. Drug Deliv. 2011, 8:415-433.
265. Dou Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery (vol 108, pg 2827, 2006). Blood 2007, 109:1816-1816.
266. Beduneau A., Ma Z.Y., Grotepas C.B., Kabanov A., Rabinow B.E., Gong N., Mosley R.L., Dou H.Y., Boska M.D., Gendelman H.E. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PloS ONE 2009, 4.
267. Brynskikh A.M., Zhao Y.L., Mosley R.L., Li S., Boska M.D., Klyachko N.L., Kabanov A.V., Gendelman H.E., Batrakova E.V. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine 2010, 5:379-396.
268. Haney M.J., Zhao Y.L., Harrison E.B., Mahajan V., Ahmed S., He Z.J., Suresh P., Hingtgen S.D., Klyachko N.L., Mosley R.L., Gendelman H.E., Kabanov A.V., Batrakova E.V. Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PloS ONE 2013, 8.
269. Haney M.J., Zhao Y.L., Li S., Higginbotham S.M., Booth S.L., Han H.Y., Vetro J.A., Mosley R.L., Kabanov A.V., Gendelman H.E., Batrakova E.V. Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine 2011, 6:1215-1230.
270. Puligujja P., McMillan J., Kendrick L., Li T., Balkundi S., Smith N., Veerubhotla R.S., Edagwa B.J., Kabanov A.V., Bronich T., Gendelman H.E., Liu X.M. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 2013, (in press). 10.1016/j.nano.2013.05.003.
271. Luxenhofer R., Schulz A., Roques C., Li S., Bronich T.K., Batrakova E.V., Jordan R., Kabanov A.V. Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials 2010, 31:4972-4979.